Maravai LifeSciences Holdings, Inc.
General ticker "MRVI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $788.9M (TTM average)
Maravai LifeSciences Holdings, Inc. follows the US Stock Market performance with the rate: 62.3%.
Estimated limits based on current volatility of 2.3%: low 4.77$, high 4.99$
Factors to consider:
- Total employees count: 570 (0.0%) as of 2024
- North America accounted for 48.8% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Dependency on cleancap sales, Customer demand risks, Labor/talent shortage/retention, Product quality issues, Government policy changes
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.65$, 6.56$]
- 2026-12-31 to 2027-12-31 estimated range: [2.60$, 6.35$]
Financial Metrics affecting the MRVI estimates:
- Positive: with PPE of -12.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: -5.39 < Operating profit margin, % of -3.50
- Positive: 19.24 < Shareholder equity ratio, % of 27.56 <= 42.59
- Negative: negative Net income
- Positive: -14.17 < Investing cash flow per share per price, % of -6.44
Short-term MRVI quotes
Long-term MRVI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $288.94MM | $259.19MM | $185.74MM |
| Operating Expenses | $320.59MM | $494.80MM | $192.48MM |
| Operating Income | $-31.65MM | $-235.62MM | $-6.74MM |
| Non-Operating Income | $649.38MM | $-25.86MM | $-228.24MM |
| Interest Expense | $45.89MM | $47.70MM | $26.99MM |
| R&D Expense | $17.28MM | $19.22MM | $17.40MM |
| Income(Loss) | $617.74MM | $-261.48MM | $-234.97MM |
| Taxes | $756.11MM | $-1.86MM | $-4.21MM |
| Net Income(Loss)* | $-119.03MM | $-144.85MM | $-130.77MM |
| Stockholders Equity | $416.75MM | $325.29MM | $212.38MM |
| Inventory | $51.40MM | $50.08MM | $40.49MM |
| Assets | $1,487.45MM | $1,008.24MM | $770.58MM |
| Operating Cash Flow | $126.22MM | $7.46MM | $-57.57MM |
| Capital expenditure | $65.55MM | $29.66MM | $13.15MM |
| Investing Cash Flow | $-122.31MM | $-24.32MM | $-31.41MM |
| Financing Cash Flow | $-61.09MM | $-235.71MM | $-16.50MM |
| Earnings Per Share** | $-0.90 | $-1.05 | $-0.90 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.